Summary of Purpose
Letigen® was a combination drug containing ephedrine, an adrenergic agonist with lipolytic and appetite-inhibiting properties. The drug was used as adjuvant treatment of obesity from 1990 and up to 2002 when it was withdrawn from the market by the manufacturer. The basis for this was a number of spontaneous reports about patients that died during treatment with Letigen®. The causal relation has never been...Read More →
The following dates are available for this trial. Trial information last updated on 5 June 2008.
|1 May 2006||3 Jun 2008||1 May 2006||1 Aug 2007||1 Jun 2008||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Perspective: Retrospective